NeurAxis, Inc.
NeurAxis, Inc. Q4 FY2025 earnings call
March 19, 2026 · fiscal period ended 2025-12
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2026-03-19
Management highlights
Brian highlighted continued commercialization strategy for IV Stems. Reimbursement progress with Category 1 CPT code and coverage. First quarter performance with clearer growth roadmap. Focus on expanding medical policy coverage and commercial footprint. Adult strategy with RCT at Cleveland Clinic and VA FSS contract.
Segment performance
Fourth quarter 2025 revenue was $968,000, up 27% from $761,000 in Q4 2024. FY 2025 revenue was $3.6 million, up 33% from $2.7 million in FY 2024. Unit deliveries increased, gross margin had fluctuations due to mix shifts and inventory factors.
Guidance
Q1 performance better than expected. Execution is key driver of growth in 2026. Focus on expanding coverage and commercial footprint.
Risks
Risks include need for continued expansion of medical policy coverage, adult payer coverage likely requiring large RCT, VA adoption timelines.
Q&A highlights
Q: Chase Knickerbocker asked about PA requests, payer coverage; A: Brian responded on PA submissions and payer coverage details.
Q: Lindsey Leeds asked about hospital staff and VA program; A: Brian answered on staff needs and VA adoption.
Q: Karen Sterling asked about adult IV stem trial; A: Brian detailed adult trial and other studies.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | $-0.17 | $-0.21 | +20.9% | $-0.21 |
| Revenue | $968,000 | $850,000 | +13.9% | $761,165 |
Transcript
March 19, 2026Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.